186 related articles for article (PubMed ID: 38338642)
1. Nonspecific Inhibition of IL6 Family Cytokine Signalling by Soluble gp130.
Widjaja AA; Cook SA
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338642
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease.
Schreiber S; Aden K; Bernardes JP; Conrad C; Tran F; Höper H; Volk V; Mishra N; Blase JI; Nikolaus S; Bethge J; Kühbacher T; Röcken C; Chen M; Cottingham I; Petri N; Rasmussen BB; Lokau J; Lenk L; Garbers C; Feuerhake F; Rose-John S; Waetzig GH; Rosenstiel P
Gastroenterology; 2021 Jun; 160(7):2354-2366.e11. PubMed ID: 33667488
[TBL] [Abstract][Full Text] [Related]
3. Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.
Wolf J; Waetzig GH; Chalaris A; Reinheimer TM; Wege H; Rose-John S; Garbers C
J Biol Chem; 2016 Jul; 291(31):16186-96. PubMed ID: 27226573
[TBL] [Abstract][Full Text] [Related]
4. Targeting IL-6 trans-signalling: past, present and future prospects.
Rose-John S; Jenkins BJ; Garbers C; Moll JM; Scheller J
Nat Rev Immunol; 2023 Oct; 23(10):666-681. PubMed ID: 37069261
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
Garbers C; Thaiss W; Jones GW; Waetzig GH; Lorenzen I; Guilhot F; Lissilaa R; Ferlin WG; Grötzinger J; Jones SA; Rose-John S; Scheller J
J Biol Chem; 2011 Dec; 286(50):42959-70. PubMed ID: 21990364
[TBL] [Abstract][Full Text] [Related]
6. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain.
Campbell IL; Erta M; Lim SL; Frausto R; May U; Rose-John S; Scheller J; Hidalgo J
J Neurosci; 2014 Feb; 34(7):2503-13. PubMed ID: 24523541
[TBL] [Abstract][Full Text] [Related]
7. Expression of Interleukin 6 signaling receptors in carotid atherosclerosis.
Ziegler L; Lundqvist J; Dreij K; Wallén H; de Faire U; Paulsson-Berne G; Hedin U; Matic L; Gigante B
Vasc Med; 2021 Feb; 26(1):3-10. PubMed ID: 33350884
[TBL] [Abstract][Full Text] [Related]
8. The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation.
Rose-John S
Clin Pharmacol Ther; 2017 Oct; 102(4):591-598. PubMed ID: 28675418
[TBL] [Abstract][Full Text] [Related]
9. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses.
Lamertz L; Rummel F; Polz R; Baran P; Hansen S; Waetzig GH; Moll JM; Floss DM; Scheller J
Sci Signal; 2018 Oct; 11(550):. PubMed ID: 30279168
[TBL] [Abstract][Full Text] [Related]
10. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
Wu X; Cao Y; Xiao H; Li C; Lin J
Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
[TBL] [Abstract][Full Text] [Related]
11. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation.
Rabe B; Chalaris A; May U; Waetzig GH; Seegert D; Williams AS; Jones SA; Rose-John S; Scheller J
Blood; 2008 Feb; 111(3):1021-8. PubMed ID: 17989316
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-11-driven gastric tumourigenesis is independent of trans-signalling.
Balic JJ; Garbers C; Rose-John S; Yu L; Jenkins BJ
Cytokine; 2017 Apr; 92():118-123. PubMed ID: 28160627
[TBL] [Abstract][Full Text] [Related]
13. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
14. The classic signalling and trans-signalling of interleukin-6 are both injurious in podocyte under high glucose exposure.
Lei CT; Su H; Ye C; Tang H; Gao P; Wan C; He FF; Wang YM; Zhang C
J Cell Mol Med; 2018 Jan; 22(1):251-260. PubMed ID: 28881473
[TBL] [Abstract][Full Text] [Related]
15. Expression and regulation of interleukin 6 and its receptor at the maternal-conceptus interface during pregnancy in pigs.
Yoo I; Han J; Kim M; Jang H; Sa S; Choi SH; Ka H
Theriogenology; 2017 Jul; 96():85-91. PubMed ID: 28532843
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Chalaris A; Schmidt-Arras D; Yamamoto K; Rose-John S
Dig Dis; 2012; 30(5):492-9. PubMed ID: 23108305
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits T
Heise D; Derrac Soria A; Hansen S; Dambietz C; Akbarzadeh M; Berg AF; Waetzig GH; Jones SA; Dvorsky R; Ahmadian MR; Scheller J; Moll JM
Sci Signal; 2021 Aug; 14(696):. PubMed ID: 34404751
[TBL] [Abstract][Full Text] [Related]
18. Differential expression and effects of gp130 cytokines and receptors in prostate cancer cells.
Palmer J; Hertzog PJ; Hammacher A
Int J Biochem Cell Biol; 2004 Nov; 36(11):2258-69. PubMed ID: 15313471
[TBL] [Abstract][Full Text] [Related]
19. Effects of blockade of peripheral interleukin-6 trans-signaling on hippocampus-dependent and independent memory in mice.
Braun O; Dewitz C; Möller-Hackbarth K; Scheller J; Schiffelholz T; Baier PC; Rose-John S
J Interferon Cytokine Res; 2013 May; 33(5):254-60. PubMed ID: 23215755
[TBL] [Abstract][Full Text] [Related]
20. Rapid monocyte infiltration following retinal detachment is dependent on non-canonical IL6 signaling through gp130.
Wang X; Miller EB; Goswami M; Zhang P; Ronning KE; Karlen SJ; Zawadzki RJ; Pugh EN; Burns ME
J Neuroinflammation; 2017 Jun; 14(1):121. PubMed ID: 28645275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
